Next CBD Product With False Claims Gets FTC Investigation, Not A Warning Letter

"Warning letter phase is over ... We will be opening investigations and we will target companies making disease claims for CBD products," says FTC attorney Rich Cleland. Agency also looking to hold retailers responsible for third-party vendors' false claims.

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.

Don't expect the US Federal Trade Commission to submit additional warning letters about false claims for cannabidiol-containing consumer health products. That's because the commission will investigate the next firm linked to the noncompliant advertising.

"We've now got six warning letters out there on CBD. The warning letter phase is over. Going forward we will not be issuing warning letters

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America